BlackRock Health Sciences Trust (BME) - NYSE
  • Mon, Jul. 11, 1:14 PM
    • BlackRock Resources and Commodities Strategy Trust (NYSE:BCX) distribution of $0.0446.
    • BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ) distribution of $0.0467.
    • BlackRock Energy and Resources Trust (NYSE:BGR) distribution of $0.0776.
    • BlackRock International Growth and Income Trust (NYSE:BGY) distribution of $0.0380.
    • BlackRock Health Sciences Trust (NYSE:BME) distribution of $0.2000.
    • BlackRock Enhanced Capital and Income Fund (NYSE:CII) distribution of $0.1000.
    • BlackRock Global Opportunities Equity Trust (NYSE:BOE) distribution of $0.0780.
    • BlackRock Utility and Infrastructure Trust (NYSE:BUI) distribution of $0.1210.
    • BlackRock Science and Technology Trust (NYSE:BST) distribution of $0.1000.
    • Payable July 29; for shareholders of record July 15; ex-div July 13.
    • Press Release
    | Mon, Jul. 11, 1:14 PM
  • Thu, Jun. 9, 11:13 AM
    • The FDA, along with international regulatory and law enforcement agencies in an initiative called Operation Pangea IX, took action against 4,402 websites engaged in the illegal selling of unapproved prescription drugs to U.S. consumers. The operation was part of a global coordinated effort led by INTERPOL called IIWA to stop the sale and distribution of illegal and potentially counterfeit medications on the internet.
    • The goal of Operation Pangea IX was to identify the manufacturers and distributors of the illegal meds and to remove the products from the supply chain. The FDA's enforcement action, which ran from May 31 to June 7, included formal complaints to domain registrars requesting the suspension of 4,402 websites, including 110 sites that sell 2,4-Dinitrophenol (DNP), typically used as a dye, wood preserver and herbicide, but never approved in the U.S. as a drug.
    • The FDA has been investigating the distribution of DNP for some time. Last month, a Bakersfield, CA man pleaded guilty to interstate commerce of an unapproved drug based on the work by an agency task force. In 2013, one of his DNP customers died after ingesting it.
    • ETFs: GRX, IRY, IXJ, BME, THW, GNRX
    | Thu, Jun. 9, 11:13 AM | 1 Comment
  • Tue, Jun. 7, 1:11 PM
    • BlackRock Resources and Commodities Strategy Trust (NYSE:BCX) distribution of $0.0446.
    • BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ) distribution of $0.0467.
    • BlackRock Energy and Resources Trust (NYSE:BGR) distribution of $0.0776.
    • BlackRock International Growth and Income Trust (NYSE:BGY) distribution of $0.0490.
    • BlackRock Health Sciences Trust (NYSE:BME) distribution of $0.2000.
    • BlackRock Enhanced Capital and Income Fund (NYSE:CII) distribution of $0.1000.
    • BlackRock Global Opportunities Equity Trust (NYSE:BOE) distribution of $0.0970.
    • BlackRock Utility and Infrastructure Trust (NYSE:BUI) distribution of $0.1210.
    • BlackRock Science and Technology Trust (NYSE:BST) distribution of $0.1000.
    • Payable June 30; for shareholders of record June 15; ex-div June 13.
    • Press Release
    | Tue, Jun. 7, 1:11 PM | 1 Comment
  • Thu, May 12, 12:51 PM
    • BlackRock Resources and Commodities Strategy Trust (NYSE:BCX) announces monthly distribution of $0.0446.
    • BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ) announces monthly distribution of $0.0467.
    • BlackRock Energy and Resources Trust (NYSE:BGR) announces monthly distribution of $0.0776.
    • BlackRock International Growth and Income Trust (NYSE:BGY) announces monthly distribution of $0.0490.
    • BlackRock Health Sciences Trust (NYSE:BME) announces monthly distribution of $0.2000.
    • BlackRock Enhanced Capital and Income Fund (NYSE:CII) announces monthly distribution of $0.1000.
    • BlackRock Global Opportunities Equity Trust (NYSE:BOE) announces monthly distribution of $0.0970.
    • BlackRock Utility and Infrastructure Trust (NYSE:BUI) announces monthly distribution of $0.1210.
    • BlackRock Science and Technology Trust (NYSE:BST) announces monthly distribution of $0.1000.
    • Payable May 31; for shareholders of record May 16; ex-div May 12.
    • Press Release
    | Thu, May 12, 12:51 PM | 3 Comments
  • Tue, Apr. 12, 6:17 PM
    • BlackRock declares dividend on Equity Funds BlackRock Resources and Commodities Strategy Trust (NYSE:BCX) announces monthly distribution of $0.0446.
    • BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ) announces monthly distribution of $0.0467.
    • BlackRock Energy and Resources Trust (NYSE:BGR) announces monthly distribution of $0.0776.
    • BlackRock International Growth and Income Trust (NYSE:BGY) announces monthly distribution of $0.0490.
    • BlackRock Health Sciences Trust (NYSE:BME) announces monthly distribution of $0.2000.
    • BlackRock Enhanced Capital and Income Fund (NYSE:CII) announces monthly distribution of $0.1000.
    • BlackRock Global Opportunities Equity Trust (NYSE:BOE) announces monthly distribution of $0.0970.
    • BlackRock Utility and Infrastructure Trust (NYSE:BUI) announces monthly distribution of $0.1210.
    • BlackRock Science and Technology Trust (NYSE:BST) announces monthly distribution of $0.1000.
    • Payable Apr 29; for shareholders of record Apr 15; ex-div Apr. 13.
    • Press Release
    | Tue, Apr. 12, 6:17 PM
  • Fri, Mar. 11, 12:17 PM
    | Fri, Mar. 11, 12:17 PM
  • Thu, Feb. 11, 12:22 PM
    | Thu, Feb. 11, 12:22 PM
  • Wed, Jan. 20, 12:03 PM
    • Even critics of Roche's (OTCQX:RHHBY -2.1%) consistent opposition to the off-label use of cancer med Avastin (bevacizumab) for wet age-related macular degeneration (wet AMD) instead of the pricier Lucentis (ranibizumab) now must concede that its view is credible as it relates to patient safety.
    • In cost conscious India, two states have suspended sales of Avastin after 15 wet AMD patients experienced pain and swelling in their eyes after receiving the medication. The company's India unit stands behind the drug while emphasizing that it does not promote Avastin for unapproved uses which, of course, have not been satisfactorily vetted via clinical trials.
    • A number of countries in Europe have been receptive to the off-label use of Avastin for wet AMD considering Lucentis is 30x more expensive. France, for example, would save the equivalent of $273M each year by switching.
    • Manufacturers have fought back. In September, an industry group filed a complaint with the European Commission arguing that French regulators' approval of Avastin for wet AMD is contrary to the EU approval process for medicines and "puts patients' health at risk."
    • The differing cost/benefit viewpoints will, no doubt, persist indefinitely as more and more expensive biologics reach the market.
    • ETFs: BIB, GRX, IRY, BIS, IXJ, BME, CNCR, THW
    | Wed, Jan. 20, 12:03 PM | 1 Comment
  • Thu, Jan. 14, 10:57 AM
    • Biotechs are moving in sync with the market today. The iShares Nasdaq Biotech Index Fund (IBB +1.8%) is up ~4% from its low of 273.47, outpacing the Nasdaq Composite's 2.6% jump from its intraday low of 4,470.59. The IBB had lost over 20% of its value since late December.
    • ETFs: BIB, GRX, IRY, BIS, IXJ, BME, CNCR, THW
    | Thu, Jan. 14, 10:57 AM | 2 Comments
  • Tue, Jan. 12, 12:53 PM
    | Tue, Jan. 12, 12:53 PM
  • Tue, Jan. 12, 11:26 AM
    • The FDA approved 45 new drugs in 2015, second only to 1996's 53. 16 (36%) were first-in-class treatments and 21 (47%) were for rare diseases.
    • Among the new molecular entities cleared last year were Novartis' Cosentyx (secukinumab) for psoriasis, Farydak (panobinostat) for multiple myeloma and Entresto (sacubitril/valsartan) for heart failure, Pfizer's Ibrance (palbociclib) for breast cancer, Sanofi/Regeneron's Praluent and Amgen's Repatha for lowering cholesterol and Eli Lilly's Portrazza (necitumumab) for lung cancer.
    • 2016 should be another strong year for drug approvals, stoked by the FDA's accelerated review designations: Fast Track, Breakthrough Therapy and Priority Review.
    • ETFs: BIB, GRX, IRY, BIS, IXJ, BME, CNCR, THW
    | Tue, Jan. 12, 11:26 AM
  • Dec. 16, 2015, 4:17 PM
    | Dec. 16, 2015, 4:17 PM
  • Nov. 19, 2015, 3:25 PM
    • The FDA issues its first approval for a genetically engineered (GE) food, AquaAdvantage Salmon grown by Maynard, MA-based AquaBounty Technologies, a majority-owned subsidiary of Intrexon (XON +4.5%). The company introduces a recombinant DNA construct into the fish which enables them to grow faster and reach market size more quickly.
    • Based on its comprehensive review of the scientific evidence, the FDA determined that the GE salmon is nutritious and safe to consume with no biologically relevant differences in the nutritional profile of AquaAdvantage Salmon and other farm-raised Atlantic salmon.
    • The approval applies to only two land-based hatcheries, one in Canada and the other in Panama. No AquaAdvantage Salmon are allowed to be bred and raised in the U.S.
    • The agency regulates genetically engineered animals under the Federal Food, Drug and Cosmetic Act because the rDNA construct meets the definition of a drug.
    • ETFs: KXI, IPS
    • ETFs: GRX, IRY, IXJ, BME
    | Nov. 19, 2015, 3:25 PM | 1 Comment
  • Nov. 12, 2015, 11:59 AM
    • A study by not-for-profit ethics and governance watchdog Bioethics International (BI) of all clinical trials submitted to the FDA for drugs approved in 2012 showed a wide range of disclosure of results with almost all falling far short of full transparency. The lack of sharing of all trial data has been one contributor to the erosion of public trust in drug companies. According to BI President Jennifer Miller, Ph.D., only 12% of Americans believe that pharmaceutical firms are honest and ethical.
    • Companies were ranked by both legal requirements to disclose data per the 2007 U.S. Food and Drug Administration Amendments Act (FDAAA) and the ethical standard that all human-based research should be publicly available in order to contribute to generalized knowledge.
    • The cross-sectional analysis of the 2012 data showed that 39 new medicines and 48 new drug entities were cleared by the FDA, 15 by 10 large firms. Researchers identified 318 relevant clinical studies (out of a total of 342) involving 99,599 participants. A median of 57% of the trials were registered, 20% reported results in clinicaltrials.gov, 56% were published and 65% were either published or reported results. Almost half of all reviewed drugs had at least one undisclosed Phase 2 or 3 study.
    • Gilead Sciences (GILD -1.1%) didn't fare too well, providing only 21% of the data on its HIV combo med Stribild. Sanofi (SNY -3%) was also cited for its lack of reported data on MS drug Aubagio. Firms scoring well included GlaxoSmithKline (GSK -1.2%), Johnson & Johnson (JNJ -0.9%) and Pfizer (PFE -0.4%). All disclosed 100% of their trial data for at least one drug.
    • BI is in the process of expanding its rankings to include other years.
    • On a positive note, the major players have indicated a keen interest in doing a better job sharing trial data, motivated, no doubt, by the work of interested observers such as BI.
    • ETFs: BIB, BIS GRX, IRY, IXJ, BME
    | Nov. 12, 2015, 11:59 AM | 61 Comments
  • Nov. 12, 2015, 10:11 AM
    | Nov. 12, 2015, 10:11 AM
  • Oct. 13, 2015, 5:26 PM
    | Oct. 13, 2015, 5:26 PM
Company Description
Under normal market conditions the Fund will invest at least 80% if its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Fund will
Sector: Healthcare
Industry: Closed-End Fund - Equity
Country: United States